Anebulo Pharmaceuticals remains a clinical-stage, pre-revenue biotechnology company focused on treatments for acute cannabinoid intoxication and substance addiction. In QQ4 2024, the company reported operating expenses of $1.34 million and a net loss of $1.35 million, with no revenue. The quarter generated a negative EBITDA of $1.29 million and a cash burn of approximately $2.05 million, leaving cash and cash equivalents of $3.09 million at quarter-end. While the balance sheet displays strong liquidity metrics (current ratio of 13.46 and a cash position that supports short-term liquidity), the company carries a sizable accumulated deficit (-$65.40 million) and depends on external funding to sustain operations absent revenue generation. The near-term outlook hinges on progression of ANEB001 and any forthcoming financing or partnering activity, as the company’s forward guidance, if any, is not provided in the supplied data.